Profit Surge, Dividend Hike
Pro Medicus Reports Doubled FY26 Profit and Higher Dividends Amid Strong Growth
Key Points
Pro Medicus announced an ordinary fully franked dividend of AUD 0.37 per security for FY26, with ex-dividend date 7 September 2026, record date 8 September 2026 and payment date 29 September 2026 (100% franked, no dividend reinvestment plan).
Appendix 4G Key to Disclosures confirms the corporate governance statement for the year ended 30 June 2026 has been approved by the board, and the company states it followed all Corporate Governance Council recommendations in full, with the board charter disclosed on its website.
Pro Medicus’ governance updates show seven directors as at 30 June 2026 and updated board and Audit & Risk Committee Charters to include enhanced oversight of climate-related risks and sustainability, plus an operational net-zero commitment for Scope 1 and 2 emissions (Board Charter Version 1.3, June 2026).
Currency translation impact in FY26 included revenue being reduced by just under US$12 million and NPAT by about US$9.8 million due to a stronger Australian dollar; the company notes hedging and a natural hedge from the US as its largest cost base.
FY26 was the second-biggest year for new contracts after FY25’s Trinity win, with six major renewals; late FY26 implementations are expected to lift FY27 revenue as a full 12 months of revenue from those contracts is realized, with expanded modules including digital pathology and AI-driven reporting platform, and US rollout planned for early 2027.
Pro Medicus (ASX: PME) delivered a standout FY2026 result, posting revenue of A$261.7 million — up 22.9% — and underlying net profit after tax of A$144.7 million, up 24.1%, according to Motley Fool Australia. The medical imaging software company also lifted its fully franked dividend to A$0.37 per share for the year, rewarding shareholders after what management called the second-biggest year for new contracts in the company's history.
Net profit attributable to members more than doubled to A$265.3 million, boosted by fair value gains that pushed reported pre-tax profit to A$377.5 million. The company signed A$407 million in new contracts during the year, per Kalkine, setting the stage for further revenue growth in FY27 as major deployments ramp up.
Second-Biggest Contract Year Fuels FY27 Revenue Pipeline
FY26 featured six major contract renewals and A$407 million in new signings, making it the second-largest contract year after FY25's landmark Trinity win, according to Kalkine. Late-year implementations mean Pro Medicus will recognise a full 12 months of revenue from those deals in FY27, giving the company a strong built-in growth tailwind heading into the new fiscal year.
New modules are also expanding the revenue base. The company plans a US rollout of its digital pathology and AI-driven reporting platform in early 2027. Management highlighted these as key drivers of its "One Platform" strategy — a single integrated system that bundles imaging, pathology, and AI tools for hospital clients.
Strong Aussie Dollar Trimmed US$12 Million From Revenue
Currency movements were a headwind in FY26. A stronger Australian dollar cut revenue by just under US$12 million and reduced net profit after tax by about US$9.8 million. Because Pro Medicus earns most of its revenue in US dollars but reports in Australian dollars, a rising Aussie dollar shrinks those earnings when converted back.
The company said it benefits from a partial natural hedge — the US is also its largest cost base, so US-dollar expenses offset some of the currency drag. Management noted it also uses hedging tools to manage the remaining exposure. Despite this, underlying EBIT still reached A$196.1 million, per Kalkine.
Dividend Lifted, Balance Sheet Strengthened Into FY27
The board declared a fully franked ordinary dividend of A$0.37 per share, according to Motley Fool Australia. Shareholders must be on the register by 8 September 2026 to receive the payment, which lands on 29 September 2026. The company runs no dividend reinvestment plan, so all payments are made in cash. Net tangible assets per security rose to A$4.10.
Governance Overhaul Adds Climate and Sustainability Rules
Pro Medicus updated its Board Charter (Version 1.3, June 2026) to include direct oversight of climate-related risks, per TipRanks. The board also committed to operational net-zero for Scope 1 and 2 emissions — that is, emissions from its own operations and purchased energy. The Audit & Risk Committee charter was updated to match, giving it a formal sustainability mandate.
The changes come ahead of mandatory sustainability reporting under Australian standard AASB S2, which took effect from 1 July 2026, according to TipRanks. The company confirmed all seven directors on its board met the full Corporate Governance Council recommendations for the year ended 30 June 2026. A Gender Equality Action Plan was also among the governance disclosures lodged with the ASX on 14 August 2026.
Sentiment
Mostly PositivePublishers
10
Articles
7
Reach
17
